Cargando…

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()

INTRODUCTION: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a treatment option in the second- or third-line palliative setting in EGFR wild-type (wt) non–small cell lung cancer (NSCLC) patients. However, response rates are low, and only approximately 25% will achieve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winther-Larsen, Anne, Fledelius, Joan, Demuth, Christina, Bylov, Catharina M, Meldgaard, Peter, Sorensen, Boe S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2016
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094375/ https://www.ncbi.nlm.nih.gov/pubmed/27816687 http://dx.doi.org/10.1016/j.tranon.2016.09.003

Ejemplares similares

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients
por: Winther-Larsen, Anne, et al.
Publicado: (2017)

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations
por: Demuth, Christina, et al.
Publicado: (2018)

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
por: Demuth, Christina, et al.
Publicado: (2017)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

cGAS-STING pathway expression as a prognostic tool in NSCLC
por: Raaby Gammelgaard, Kristine, et al.
Publicado: (2021)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells
por: Jakobsen, K R, et al.
Publicado: (2017)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy
por: Zhou, Xin, et al.
Publicado: (2021)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC
por: Gammelgaard, Kristine Raaby, et al.
Publicado: (2018)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
por: Hussmann, Dianna, et al.
Publicado: (2017)

Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients
por: Madsen, Anne Tranberg, et al.
Publicado: (2020)

EGFR transcription in non‐small‐cell lung cancer tumours can be revealed in ctDNA by cell‐free chromatin immunoprecipitation (cfChIP)
por: Månsson, Christoffer Trier, et al.
Publicado: (2021)

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

Hematogenous muscular metastasis of NSCLC in FDG-PET/CT
por: Satoh, Hiroaki, et al.
Publicado: (2015)

Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
por: Sorensen, Boe S, et al.
Publicado: (2014)

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study
por: Dissing, Julie Gabe, et al.
Publicado: (2022)

Neurofilament Light Chain as A Biomarker for Brain Metastases
por: Winther-Larsen, Anne, et al.
Publicado: (2020)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
por: Zwitter, Matjaz, et al.
Publicado: (2014)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy
por: Fledelius, Joan, et al.
Publicado: (2016)

Predictive Power of a Radiomic Signature Based on (18)F-FDG PET/CT Images for EGFR Mutational Status in NSCLC
por: Li, Xiaofeng, et al.
Publicado: (2019)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
por: Cavazzoni, Andrea, et al.
Publicado: (2012)

Day-to-day and within-day biological variation of cell-free DNA
por: Madsen, Anne Tranberg, et al.
Publicado: (2019)

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
por: Zou, Bin, et al.
Publicado: (2018)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
por: Seki, Nobuhiko, et al.
Publicado: (2019)

Gene Expression of the EGF System—a Prognostic Model in Non–Small Cell Lung Cancer Patients Without Activating EGFR Mutations()
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2016)

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
por: Chen, M-C, et al.
Publicado: (2013)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
por: Zwitter, Matjaz, et al.
Publicado: (2016)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
por: Huang, Yanping, et al.
Publicado: (2023)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
por: Walleser, Silke, et al.
Publicado: (2012)

A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
por: Wang, Duo, et al.
Publicado: (2021)

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review
por: Wang, Qian, et al.
Publicado: (2022)

Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients
por: Trier Maansson, Christoffer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_796ins4jsjead95fv1k94uqe68